Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12496670 | 0.89 | LOXL2 (0.52) | HRH3AKT2CSNK2A1TAAR1NSD2 | |
| SCHEMBL2572842 | 0.88 | CSNK2A1 (0.62) | CSNK2A1TAAR1NSD2HTR7LOXL2 | |
| SCHEMBL3790212 | 0.86 | HTR7 (0.56) | HRH3CSNK2A1TAAR1NSD2CD274 | |
| SCHEMBL3780634 | 0.83 | HRH3 (0.52) | HRH3AKT2CSNK2A1TAAR1CD274 | |
| SCHEMBL20938020 | 0.81 | NSD2 (0.44) | HRH3AKT2NSD2DGAT1SOAT1 | |
| SCHEMBL3793564 | 0.79 | HTR7 (0.56) | HRH3AKT2CSNK2A1TAAR1CD274 | |
| SCHEMBL15353584 | 0.77 | WNT3A (0.46) | NSD2LOXL2 | |
| SCHEMBL22400156 | 0.76 | HRH3 (0.48) | HRH3AKT2TAAR1CD274NOS3 | |
| SCHEMBL26032092 | 0.75 | RARB (0.39) | DGAT1SOAT1RARB | |
| SCHEMBL11480904 | 0.75 | RARB (0.39) | HRH3DGAT1SOAT1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | HRH3 169/4885AKT2 3144/4885CSNK2A1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.